Halozyme (NASDAQ: HALO) grants 10,000 RSUs to interim CFO Ramsay

Rhea-AI Filing Summary

RAMSAY DAVID A reported acquisition or exercise transactions in this Form 4 filing.

HALOZYME THERAPEUTICS, INC. reported that interim CFO David A. Ramsay received a grant of 10,000 Restricted Stock Units tied to the company’s common stock. These RSUs were awarded as compensation rather than through an open-market purchase or sale.

The award vests in full on June 30, 2026, provided he remains employed through that date. After vesting, the shares are subject to a one-year holding period, meaning he must continue to hold the resulting shares for an additional year. Following this grant, his directly held RSU-related position from this award is 10,000 units.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider RAMSAY DAVID A

Role Interim CFO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	10,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 10,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 10,000 units Total units after grant: 10,000 units Vesting date: June 30, 2026 +2 more

5 metrics

RSU grant size 10,000 units Restricted Stock Units granted to interim CFO

Total units after grant 10,000 units Total RSUs held from this award following transaction

Vesting date June 30, 2026 RSUs vest in full if employment continues

Holding period One year Post-vesting holding period for vested shares

Grant price per unit $0.0000 Compensation grant, not open-market purchase

Key Terms

Restricted Stock Units, vesting, one-year holding period, grant/award acquisition

4 terms

Restricted Stock Units financial

"The 10,000 Restricted Stock Units granted to David A. Ramsay"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"This award vests in full on June 30, 2026 provided the Reporting Person remains employed"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

one-year holding period financial

"and is subject to a one-year holding period from the vesting date"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAMSAY DAVID A

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	04/01/2026		A		10,000		06/30/2026(1)	(1)	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. This award vests in full on June 30, 2026 provided the Reporting Person remains employed through such date and is subject to a one-year holding period from the vesting date.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did HALOZYME (HALO) disclose for David A. Ramsay?

HALOZYME disclosed that interim CFO David A. Ramsay received a grant of 10,000 Restricted Stock Units. These units are compensation-based awards linked to common stock, not an open-market purchase or sale of existing shares.

When do David A. Ramsay’s 10,000 HALO Restricted Stock Units vest?

The 10,000 Restricted Stock Units granted to David A. Ramsay vest in full on June 30, 2026. Vesting is contingent on him remaining employed through that date, aligning the award with continued service at HALOZYME.

Is there a holding period on David A. Ramsay’s HALO Restricted Stock Units?

Yes. After the 10,000 Restricted Stock Units vest on June 30, 2026, the resulting shares are subject to a one-year holding period. This means he must retain those shares for an additional year after vesting.

How many HALOZYME-related units does David A. Ramsay hold after this award?

Following the grant, David A. Ramsay holds 10,000 Restricted Stock Units from this award. These RSUs represent a right to receive an equal number of common shares upon vesting and settlement, subject to the stated vesting and holding conditions.

Was David A. Ramsay’s HALO transaction a stock purchase or sale?

No. The Form 4 shows a grant of 10,000 Restricted Stock Units as compensation, not a market transaction. The filing does not report any open-market buying or selling of HALOZYME common stock by David A. Ramsay on this date.